Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 307 of the 310 references it cites were found in a registry or an index.
Abstract
Neurodegeneration is a chronic progressive loss of neuronal cells leading to deterioration of central nervous system (CNS) functionality. It has been shown that neuroinflammation precedes neurodegeneration in various neurodegenerative diseases. Matrix metalloproteinases (MMPs), a protein family of zinc‐containing endopeptidases, are essential in (neuro)inflammation and might be involved in neurodegeneration. Although MMPs are indispensable for physiological development and functioning of the organism, they are often referred to as double‐edged swords due to their ability to also inflict substantial damage in various pathological conditions. MMP activity is strictly controlled, and its dysregulation leads to a variety of pathologies. Investigation of their potential use as therapeutic targets requires a better understanding of their contributions to the development of neurodegenerative diseases. Here, we review MMPs and their roles in neurodegenerative diseases: Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), and multiple sclerosis (MS). We also discuss MMP inhibition as a possible therapeutic strategy to treat neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MMP-1, cleaves the structural connective tissue components collagen type I, II and II, and is detected only at low levels under physiological conditions, but can be abnormally high in several age-associated pathologies”
From Redox control of senescence and age-related disease. (2017) · cites this paper as [137]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the association between MMP-1 and ROS and the significance of these interactions in degenerative disease etiology is well established”
From Redox control of senescence and age-related disease. (2017) · cites this paper as [137]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 1×
“Additionally, ALS is associated with protein inclusions composed mostly of transactive response DNAbinding protein 43 (TDP-43) in the cytoplasm in the affected areas of the brain and spinal cord [232].”
Background2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Visse, R., & Nagase, H. (2003) · Circulation Research · doi:10.1161/01.res.0000070112.80711.3d · Cited by 4,575 · cited 1×
“of MMPs), catalytic domain (holds the Zn ion), hinge region (connecting sequences), and C-terminal hemopexinlike domain (required for substrate and TIMP recognition) [6] (Figure 1).”
Microglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396 · cited 1×
“When triggered by various immunological stimuli, microglia morphologically transform into ameboid cells and start to proliferate and secrete inflammatory mediators [109, 110].”
BackgroundMicroglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 2×
“However, it is speculated that initial neurotoxic insult to dopaminergic neurons results in the release of certain factors that activate microglia and convert them from beneficial into harmful [121].”
BackgroundNagase, H., & Woessner, J. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21491 · Cited by 3,912
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“Besides aging, the most prominent genetic risk factor for developing late onset AD is the presence of apolipoprotein E ε4 allele (APOE ε4) in the genome [173].”
BackgroundNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · cited 1×
“Aβ deposits are typically surrounded by dystrophic neurites, reactive astrocytes, and activated microglia, forming densecore plaques in the brain parenchyma [158].”
Background
Research works printed but not linked: 4
- 10.1002/(sici)1097-4547(19981001)54:160;68::aid-jnr862;3.0.co;2-f · doi:10.1002/(sici)1097-4547(19981001)54:160;68::aid-jnr862;3.0.co;2-f
- 10.1002/1531-8249(199912)46:660;860::aid-ana862;3.0.co;2-m · doi:10.1002/1531-8249(199912)46:660;860::aid-ana862;3.0.co;2-m
- Goldenberg M. M., 2012, Multiple sclerosis review, P & T, 37, 175
- 10.1523/JNEUROSCI.0967-12.2012 · DOI · Paper page
Cited by
Items 101–200 of 203
Kaddour, H., McDew‐White, M., Madeira, M. M., Tranquille, M. A., Tsirka, S. E., Mohan, M., & Okeoma, C. M. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02586-9 · Cited by 16
“These observations are intriguing, because under pathological conditions, dysregulated expression of MMPs induces inflammation and promotes progression of neurodegenerative diseases [120].”
BackgroundShilts, J., & Broadie, K. S. (2017) · Journal of Cell Science · doi:10.1242/jcs.200808 · Cited by 17
“Motor defects have consistently been found across a range of Mmp manipulations (Brkic et al., 2015; Dansie et al., 2013; Jaworski et al., 2006; Sidhu et al., 2014), although molecular mechanisms had not been identified.”
BackgroundKuo, P., Brown, D. A., Scofield, B. A., Paraiso, H. C., Wang, P., Yu, I.-C. I., & Yen, J.-H. J. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.03.010 · Cited by 16
“CNS resident cells, including MG and brain endothelial cells, and infiltrating inflammatory immune cells are the cell populations, producing MMP3 and MMP9 under neuroinflammatory conditions (Amtul et al., 2014; Brkic et al., 2015; Yang et al., 2007).”
BackgroundProteases Upregulation in Sporadic Alzheimer’s Disease Brain
Medoro, A., Bartollino, S., Mignogna, D., Marziliano, N., Porcile, C., Nizzari, M., Florio, T., Pagano, A., Raimo, G., Intrieri, M., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181284 · Cited by 20
“…control of specific proteases and their abnormal activation, may cause the remodeling of the ECM, contributing to brain atrophy, neuroin-flammation and decreased dendritic arborization [12, 13] and, in parallel, to the aberrant processing of proteins involved in AD, mainly A (cid:2) PP [25, 34].”
Niranjan, R., Sumitha, M. K., & Kumar, A. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26903 · Cited by 18
“Metalloproteinases are one of the most important enzymes responsible for changes in extracellular matrix (Table 1).(42) They are grouped into two major classified families of zinc‐containing endopeptidases, the MMPs and a disintegrin and metalloproteinase”
BackgroundPrice, R., Mercuri, N. B., & Ledonne, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020869 · Cited by 16
“Likewise, aberrant activity of serine proteases and MMPs, possibly resulting in abnormal PARs signaling, has been linked to AD, PD, TBI, stroke, epilepsy, and familial encephalopathy with neuroserpin inclusion bodies (FENIB) [3,5,36,40–45].”
BackgroundInfluentialSerum programmed cell death proteins in amyotrophic lateral sclerosis
Beers, D. R., Zhao, W., Thonhoff, J. R., Faridar, A., Thome, A. D., Wen, S., Wang, J., & Appel, S. H. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100209 · Cited by 15
“Two separate groups have found increases in both pro-MMP-9 and active MMP-9 in sera of patients with ALS relative to HC (Brkic et al., 2015).”
BackgroundMelrose, J. (2024) · Journal of Neuroscience Research · doi:10.1002/jnr.25361 · Cited by 20
“MMPs mediate characteristic ECM changes effecting the functional properties of brain tissues in a number of neurodegenerative diseases (Brkic et al., 2015; Łukaszewicz-Zając et al., 2014; Rempe et al., 2016; Wang et al., 2014).”
Calderon, M. R., Mori, M., Kauwe, G., Farnsworth, J., Ulian-Benitez, S., Maksoud, É., Shore, J., & Haghighi, A. P. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110097119 · Cited by 16
Kim, B. J., Hong, E. P., Youn, D. H., & Jeon, J. P. (2022) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.18.2.163 · Cited by 14
Exome-wide rare variant analysis in familial essential tremor
Díez-Fairén, M., Houle, G., Ortega‐Cubero, S., Bandrés‐Ciga, S., Álvarez, I., Cárcel, M., Ibáñez, L., Fernández, M. V., Budde, J., Trotta, J.-R., et al. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.11.021 · Cited by 16
Sánchez, K. E., & Maguire‐Zeiss, K. A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.585544 · Cited by 16
Bian, Z., Liu, X., Feng, T., Yu, H., Hu, X. F., Hu, X., Bian, Y., Sun, H., Tadokoro, K., Takemoto, M., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215318 · Cited by 15
“Increased expression of MMP-9 was observed in AD patients, which had a correlation with increased BBB permeability and degradation of extracellular matrix components [48, 49].”
A modified gelatin zymography technique incorporating total protein normalization
Raykin, J., Snider, E. J., Bheri, S., Mulvihill, J. J., & Ethier, C. R. (2017) · Analytical Biochemistry · doi:10.1016/j.ab.2017.01.003 · Cited by 14
Bjørklund, G., Butnariu, M., Caunii, A., & Peana, M. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05672-8 · Cited by 13
“Additionally, by interacting with ZnT transporters, MTs regulate Zn sequestration in immune cells, preventing excessive Zn-mediated immune activation and subsequent neuroinflammation [75].”
Systems biology of Alzheimer’s Disease: a scoping review of key pathways and mechanisms
Bice, P. J., Nho, K. T., Ertekin‐Taner, N., & Saykin, A. J. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00934-4 · Cited by 18
“…plexus that make up the blood-CSF barrier of the brain parenchyma, leading to the production of cytokines and MMPs, as well as other cytotoxic factors that further disrupt the BBB and promote chronic neuroinflammation and oxidative stress, thereby increasing Aβ pathology [47, 53, 71, 98–102].”
Saatian, B., Deshpande, K., Herrera, R., Sedighi, S., Eisenbarth, R., Iyer, M., Das, D., Julian, A., Martirosian, V., Lowman, A. K., et al. (2023) · Journal of Neuroscience Research · doi:10.1002/jnr.25249 · Cited by 13
Pharmacological mechanisms of norcantharidin against hepatocellular carcinoma.
Qian, Z., Chen, Y.-J., & Bao, Y.-X. (2023) · PubMed Central · Cited by 13
Modern view on hepatic encephalopathy: basic terms and concepts of pathogenesis
Shulyatnikova, T. V., & Шаврин, В. А. (2017) · Pathologia · doi:10.14739/2310-1237.2017.3.118773 · Cited by 13
“The pathogenic effect of MMPs is manifested in increasing permeability of BBB, in the processes of demyelination, stimulation of fibrosis of blood vessels, development of gliosis, damage to neurons and other influences [52].”
BackgroundGhelfi, L., Mongan, D., Susai, S. R., Föcking, M., Cotter, D., & Cannon, M. D. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.11.035 · Cited by 12
A cell surface display fluorescent biosensor for measuring MMP14 activity in real-time
Braun, A., Farber, M. J., Klase, Z. A., Berget, P. B., & Myers, K. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-24080-0 · Cited by 12
Advances of research of Fc-fusion protein that activate NK cells for tumor immunotherapy
Niu, Y.-X., Xu, Z., Yu, L., Lu, Y., Wang, Y., Wu, C., Hou, Y.-B., Li, J., Huang, S., Song, X., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108783 · Cited by 12
Orhan, İ. E., Şenol, F. S., Salmas, R. E., Irmak, S., Özgün, Ö., Turgut, G. Ç., Şen, A., Zbancioc, A., Luca, S. V., Skiba, A., et al. (2022) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200315 · Cited by 11
“Matrix metalloproteinases (MMP) are other genes thought to play a role in the pathophysiology of AD disease.[34] MMP-9 are associated with immunological and cardiovascular diseases, cancer, and pathological processes affecting the central nervous system.”
BackgroundThe Effect of Sialic Acid on the Expression of miR-218, NF-kB, MMP-9, and TIMP-1
Sadr, N. K. S., Shafiei, M., Galehdari, H., & Khirolah, A. (2020) · Biochemical Genetics · doi:10.1007/s10528-020-09981-y · Cited by 11
Kwan, M. Y., Choo, A., Hanania, T., Ghavami, A., Beltrán, J., Shea, J., Barboza, A., Hu, A., Fowler, M., Neelagiri, V. R., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040811 · Cited by 11
“Increased expression of MMPs or an imbalance of different MMPs has been observed in a variety of pathological conditions, including various neurodegenerative diseases [10,11].”
BackgroundPromising molecular targets for pharmacological therapy of neurodegenerative pathologies
Неганова, М. Е., Aleksandrova, Y. R., Nebogatikov, V. O., Klochkov, S. G., & Ustyugov, A. A. (2020) · Acta Naturae · doi:10.32607/actanaturae.10925 · Cited by 11
Stimuli Induced Uptake of Protein‐Like Peptide Brush Polymers
Blum, A. P., Yin, J., Lin, H. H., Oliver, B. A., Kammeyer, J. K., Thompson, M. P., Gilson, M. K., & Gianneschi, N. C. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202103438 · Cited by 10
Wu, Y., Wang, Y., Han, L., Hu, Q., Xie, Y., Nan, X., He, H., & Liu, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-71817-1 · Cited by 17
“It is usually produced in its precursor form (pro-MMPs), is activated by other enzymes or free radicals through cysteine switching mechanism 22 , and participates in extracellular matrix remodeling under normal physiological and pathological conditions 23 , promotes the transformation of various…”
Molecular Mechanisms of Amyotrophic Lateral Sclerosis
Collins, M. A., & Bowser, R. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802257-3.00004-3 · Cited by 12
Moyano, P. M., Vicente-Zurdo, D., Blázquez-Barbadillo, C., Menéndez, J. C., González, J. F., Rosales‐Conrado, N., & del Pino, J. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00333 · Cited by 10
“9 Otherwise, heavy metals were also related to the induction of MMPs, which could lead to cytotoxicity.”
Matrix metalloproteinases deregulation in amyotrophic lateral sclerosis
Sánchez-Torres, J. L., Yescas, P., Torres‐Romero, J. C., Espinosa, O. R., López‐Cánovas, L., Tecalco-Cruz, Á. C., Ponce-Regalado, M. D., & Álvarez-Sánchez, M. E. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.117175 · Cited by 10
Lysosomal Function Impacts the Skeletal Muscle Extracellular Matrix
Coffey, E., Astumian, M., Alrowaished, S. S., Schaffer, C. E., & Henry, C. A. (2021) · Journal of Developmental Biology · doi:10.3390/jdb9040052 · Cited by 11
“MMP gene expression and activity is tightly regulated during development and homeostasis; however, changes in MMP expression and activity occur in many diseases [54].”
BackgroundFouad, G. I., & Ahmed, K. A. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110125 · Cited by 10
Fluid biomarkers in cerebral amyloid angiopathy
Savar, S. M., Ma, B., Hone, E., Jahan, F., Markovic, S. J., Pedrini, S., Shemehsavar, S., Easwaran, V., Taddei, K., Gardener, S. L., et al. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1347320 · Cited by 10
Protease-activated receptor 1 (PAR1) inhibits synaptic NMDARs in mouse nigral dopaminergic neurons
Price, R., Ferrari, E. S., Gardoni, F., Mercuri, N. B., & Ledonne, A. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105185 · Cited by 9
Platelet Behavior Contributes to Neuropathologies: A Focus on Alzheimer's and Parkinson's Disease
Page, M. J., & Pretorius, E. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1733960 · Cited by 12
Pathophysiology of the choroid plexus in brain diseases
Mihaljević, S., Michalicová, A., Bhide, M., & Kováč, A. (2021) · General Physiology and Biophysics · doi:10.4149/gpb_2021032 · Cited by 10
Is pseudoexfoliation glaucoma a neurodegenerative disorder?
Padhy, B., & Alone, D. P. (2021) · Journal of Biosciences · doi:10.1007/s12038-021-00217-8 · Cited by 11
“Differential expression of matrix metalloproteinases is seen to be involved in another degenerative disorder, amyotrophic lateral sclerosis (ALS) which is characterized by degeneration of motor neurons in the brain and spinal cord (Brkic et al. 2015).”
BackgroundLatronico, T., Rossano, R., Miniero, D. V., Casalino, E., & Liuzzi, G. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042142 · Cited by 8
“A high expression of MMPs is well documented in various neurological disorders including Parkinson’s disease (PD), Alzheimer’s disease (AD), and multiple sclerosis (MS) [22,23].”
BackgroundAksnes, M., Schibstad, M. H., Chaudhry, F. A., Neerland, B. E., Caplan, G. A., Saltvedt, I. T., Eldholm, R. S., Myrstad, M., Edwin, T. H., Persson, K., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00558-z · Cited by 8
“Results (lines 307-311):”
SoukhakLari, R., Moezi, L., Pirsalami, F., Ashjazadeh, N., & Moosavi, M. (2018) · PharmaNutrition · doi:10.1016/j.phanu.2018.05.002 · Cited by 8
Choi, J., Kwon, H., & Han, P. (2021) · Experimental Neurobiology · doi:10.5607/en21014 · Cited by 8
“The expression of MMP-2, MMP-9 and tPA is regulated by multiple factors associated with AD, which may include aging, stress hormones and the levels of β-amyloid [42, 43].”
BackgroundMenden, K., Francescatto, M., Nyima, T., Blauwendraat, C., Dhingra, A., Castillo-Lizardo, M., Fernandes, N., Kaurani, L., Kronenberg‐Versteeg, D., Atasu, B., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-153135/v1 · Cited by 8
Dystroglycan-HSPG interactions provide synaptic plasticity and specificity
Melrose, J. (2024) · Glycobiology · doi:10.1093/glycob/cwae051 · Cited by 10
“MMPs also have roles in the turnover of ECM components during ECM remodeling in tissue morphogenesis and normal tissue development (Brkic et al. 2015; Rempe et al. 2016) as well as in ECM repair processes.”
BackgroundSystems-level organization of extracellular proteostasis
Gomes, C. M., & Vendruscolo, M. (2026) · Science · doi:10.1126/science.aed3712 · Cited by 8
Islam, Y., Ehtezazi, P., Cashmore, A., Marinsalda, E., Leach, A. G., Coxon, C. R., Fatokun, A. A., Sexton, D. W., Khan, I., Zouganelis, G. D., et al. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.12.004 · Cited by 9
Xiao, J., Huang, J., & Yolken, R. H. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100728 · Cited by 9
“Studies have shown increased expression of MMP-9 during tissue remodeling events, such as wound healing, tumor invasion, neurogenesis, axonal growth, angiogenesis, CNS barrier disruption, myelinogenesis, and demyelination (Brkic et al., 2015).”
BackgrounddCas9-mediated transcriptional activation of tissue inhibitor of metalloproteinases
Duellman, T., Doll, A., Chen, X., Wakamiya, R., & Yang, J. (2017) · Metalloproteinases In Medicine · doi:10.2147/mnm.s146752 · Cited by 11
“In addition to the traditional role of regulating the extracellular matrix, it is now clear that MMPs play a broader role in modulating inflammation and a role in overall neuronal survival and toxicity within the nervous system.(3,4) MMPs are also recognized as playing a key role in essential activities such as neural…”
Fidler, Y., & Gomes, J. R. (2022) · The Cerebellum · doi:10.1007/s12311-022-01386-4 · Cited by 7
Moyano, P. M., Vicente-Zurdo, D., Blázquez-Barbadillo, C., Menéndez, J. C., González, J. F., Rosales‐Conrado, N., & del Pino, J. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113264 · Cited by 7
Li, W., Zhang, H., Zhang, L., Zhang, T., & Ding, H. (2022) · BioMed Research International · doi:10.1155/2022/7709926 · Cited by 8
“MMPs are involved in the degradation of the extracellular matrix, as well as the processing of growth factors, cytokines, chemokines, adhesion molecules, and several other enzymes [30, 31].”
Rocchi, D., Blázquez-Barbadillo, C., Agamennone, M., Laghezza, A., Tortorella, P., Vicente-Zurdo, D., Rosales‐Conrado, N., Moyano, P. M., del Pino, J., González, J. F., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113061 · Cited by 7
Tau Protein Modulates Perineuronal Extracellular Matrix Expression in the TauP301L-acan Mouse Model
Schmidt, S., Holzer, M., Arendt, T., Sonntag, M., & Morawski, M. (2022) · Biomolecules · doi:10.3390/biom12040505 · Cited by 9
“Investigation of post-mortem brains of AD patients showed that accumulations of MMPs and TIMPs were localized near Aβ-plaques and NFTs, thus MPs and their physiological inhibitors are assumed to be involved in the formation of these lesions [93,97].”
BackgroundN-acetyl proline-glycine-proline: implications for neurological disorders
Hill, J. W., & Nemoto, E. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.184478 · Cited by 6
“…disorders and MMPs are believed to participate in injury processes in these disorders through several mechanisms, including opening of the blood-brain barrier, direct injury to neurons through anoikis, and downregulation of neuronal DNA repair enzymes (Hill and Nemoto, 2015; Brkic et al., 2015).”
López‐Font, I., Iborra‐Lázaro, G., Sánchez‐Valle, R., Molinuevo, J. L., Cuchillo‐Ibáñez, I., & Sáez‐Valero, J. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.12.012 · Cited by 6
Molecular and Therapeutic Targets for Amyloid-beta Plaques in Alzheimer's Disease: A Review Study
Thomas, J., & WILSON, S. K. (2021) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.2021.3522.1 · Cited by 7
“MMPs are further divided into six main subgroups, of which gelatinase type (MMP-2 and 9) and membrane-type MMPs (MMP-1, 2, 3, 4, 5, and 6) play a role in AD and other neurological diseases (Wang et al., 2014; Yin et al., 2006).”
BackgroundInfluentialBowser, R. P., An, J., Schwartz, K., Sucholeiki, R. L., & Sucholeiki, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188900 · Cited by 5
“While this study focuses on understanding the relationship between MMP-2/-9 and ALS, other neurodegenerative diseases, such as Parkinson’s and Alzheimer’s disease, have also been reported to have elevated levels of various MMPs [24].”
Effects of common functional MMP12 gene polymorphisms on PD in a Polish population
Białecka, M. A., Kurzawski, M., Vlaykova, T. I., Tacheva, T., Dziedziejko, V., Pierzchlińska, A., & Droździk, M. (2017) · Neurologia i Neurochirurgia Polska · doi:10.1016/j.pjnns.2017.06.001 · Cited by 5
“However, upregulation of certain MMPs has been reported in Parkinson's disease (PD) [5].”
BackgroundRegulation of CNS Plasticity Through the Extracellular Matrix
Warren, P. M., Dickens, S., Gigout, S., Fawcett, J. W., & Kwok, J. C. F. (2018) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190635374.013.11 · Cited by 5
Huang, K.-F., Hsu, W.-C., Yu, C.-H., & Kung, W. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.233443 · Cited by 4
“These MMPs, by managing the diversity of many extracellular components involving extracellular matrix proteins and many growth factors, contribute to various physiological and pathological activities (Wojcik-Stanaszek et al., 2011; Brkic et al., 2015).”
BackgroundKaur, S., Kumar, P., & Singh, S. (2019) · Current Psychopharmacologye · doi:10.2174/2211556009666191231155927 · Cited by 5
Deciphering the focal role of endostatin in Alzheimer’s disease
Kaur, D., Behl, T., Chigurupati, S., Sehgal, A., Singh, S., Sharma, N., Badavath, V. N., Vargas-De-La-Cruz, C. B., Bhatia, S., Al‐Harrasi, A., et al. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16567-7 · Cited by 4
“…in research, the anti-MMP agent, which is presumably largely specified for MMP-9 andMMP-2, inhibits Aβ-induced liberation of lactate dehydrogenase in primary cultured neurons, proposing the contribution of MMP-9 andMMP-2 in Aβ-induced neurotoxicity (Felbor et al. 2000; Brkic et al. 2015).”
BackgroundZheng, Q., Fang, L.-Z., Huang, X., Wang, Y., & Zhang, S. (2020) · Research Square · doi:10.21203/rs.3.rs-61537/v1 · Cited by 4
Inflammatory Biomarkers in Ischemic Stroke: Mechanisms, Clinical Applications, and Future Directions
Yang, Y., Zhu, H., Xiong, T., & Li, S. (2025) · Neurosurgical Subspecialties · doi:10.14218/nsss.2025.00029 · Cited by 3
Taheri, E., & Raeeszadeh‐Sarmazdeh, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-30643-9 · Cited by 4
The Potential Use of Matrix Metalloproteinases in Alzheimer’s Disease Therapy
Krawczuk, D., & Mroczko, B. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041555 · Cited by 4
“These molecule inhibitors aim to modulate the degradation of the extracellular matrix and regulate the inflammatory processes mediated by MMPs [49].”
Trabocchi, A., & Lenci, E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823974-2.00033-4 · Cited by 5
Introduction to Neuroimmunology
Coyle, P. K. (2019) · Current clinical neurology · doi:10.1007/978-3-030-24436-1_1 · Cited by 3
Metals and amyloid gain-of-toxic mechanisms in neurodegenerative diseases
Cristóvão, J. S., Moreira, G. G., Grabrucker, A. M., & Gomes, C. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819132-3.00009-9 · Cited by 3
Influence of feelings on the blood-brain barrier (BBB) and drug delivery
Ocab, O., Saad, H. A., Mashal, R., Osama, K., Marzouk, M., & Hamdi, N. (2025) · Progress in brain research · doi:10.1016/bs.pbr.2025.03.006 · Cited by 2
Antiproliferative and apoptotic effects of Pervari honey on SH-SY5Y neuroblastoma cells
Çelik, P. A., Derya-Andeden, M., Eciroglu, H., & Dönmez‐Altuntaş, H. (2025) · Medical Oncology · doi:10.1007/s12032-025-02963-3 · Cited by 5
Matrix Metalloproteinase-9 Gene Polymorphisms in South-West Iranian Multiple Sclerosis (MS) Patients
Sadr, N. K. S., Galehdari, H., Seifi, T., Delfan, N., Khatami, S. R., & Hafizi, A. (2019) · Russian Journal of Genetics · doi:10.1134/s1022795419100107 · Cited by 2
Wang, S., Wang, N., Sheng, L., Wang, J., Song, B., Li, F., & Min, X. (2023) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2023.100736 · Cited by 2
Contribution of neuroinflammation, resolution, and neuroprotection in neuropsychiatric diseases
Farooqui, A. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-88460-0.00002-3 · Cited by 3
Contribution of neuroinflammation, resolution, and neuroprotection in neurodegenerative diseases
Farooqui, A. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-88460-0.00010-2 · Cited by 5
Ongtanasup, T., Jampa, O., Suwannakul, N., & Eawsakul, K. (2025) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/adpp/6634761 · Cited by 4
Rostagno, A. A., & Ghiso, J. A. (2025) · Antioxidants · doi:10.3390/antiox14070812 · Cited by 7
“…pathways is triggered in vitro by oligomeric forms of A β [29,141–146] and has been recapitulated in transgenic animal models [53–69], which demonstrated not only increased generation of free radicals and oxidative DNA/protein damage but also reduced glucose metabolism/ATP production [43,147–154].”
Hearst, S. M., Bednářová, A., Draughn, B., Johnson, K., Mills, D., Thomas, C., Scales, J., Keenan, E. T., Welcher, J. V., & Krishnan, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.610887 · Cited by 2
Salih, K. M., Abdullah, A. H., & Sheaheed, N. M. (2022) · Al-Mustansiriyah Journal of Sciences · doi:10.23851/mjs.v33i3.1130 · Cited by 2
“In addition, it is known that MMPs play a significant role in neuroinflammation and neurodegeneration such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis [47].”
BackgroundMatrix Metalloproteinases in Fragile X Syndrome
Ethell, D. W., & Sidhu, H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00015-9 · Cited by 2
Novel immunotherapy strategies involving matrix metalloproteinase (MMP) family
Garay-Canales, C. A., Díaz-Alvarez, L., & López-Cortés, G. I. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822028-3.00015-7 · Cited by 2
Swarnakar, S., & Jana, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101814 · Cited by 2
Bilek, F., Ercan, Z., Deniz, G., Özgül, S., & Demir, C. F. (2024) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2024.578434 · Cited by 1
CSF and plasma neuro-biomarker dynamics after gene therapy for cerebral adrenoleukodystrophy
Lund, T. C., Gupta, A. O., Kemp, S., Loes, D. J., Nascene, D. R., & Orchard, P. J. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201702 · Cited by 1
“26 Similarly, cytokines known to regulate vascular function were also assessed.”
Palmer, E., Snoddy, C. A., York, P., Davis, S., Hunter, M. F., & Krishnan, N. (2024) · Biology · doi:10.3390/biology13110854 · Cited by 3
“…in the central nervous system (CNS), MMPs are evident in a variety of roles such as with brain development, synaptic plasticity, and repairment, and they have implications in different brain disorders including Alzheimer’s, multiple sclerosis, Parkinson’s disease (PD), and more [10,11].”
Bosman, L. W. J., el Azzouzi, H., Kros, L., Ridwan, Y. R., van Vliet, N., Dijkhuizen, S., Sabel-Goedknegt, E., Generowicz, B. S., Sierksma, M. C., Jaarsma, D., et al. (2025) · PNAS Nexus · doi:10.1093/pnasnexus/pgaf359 · Cited by 1
“Indeed, the increased tortuosity of the coronary arteries in LD mice occurred alongside with increased levels of MMP activity, indicative of remodeling due extracellular matrix degradation (37, 61 – 63).”
Blood-Brain Barrier Permeability and Inflammation in Cerebral Small Vessel Disease
Walsh, J. (2019) · Apollo (University of Cambridge) · doi:10.17863/cam.50869 · Cited by 2
Dehghani, L., Sabbagh, S., Esmaeilian-Afyouni, N., Shaygannejad, V., Saboori, M., Rezvani, M., Nadeali, Z., Moayednia, M., Nouri, H., Mortazavi, Z., et al. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101061
Dai, L., Muggnyi, J., Cai, X., Mao, S., zhang, T., Shi, H., Lu, C., & Lu, C. (2021) · Research Square · doi:10.21203/rs.3.rs-547264/v1
Swarnakar, S., & Jana, S. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101814-1
The utility of metalloprotienase 9 (MMP-9) in diagnostics of ovarian cancer
Kicman, A., Kołos, J., Motyka, J., Kulesza, M., Niczyporuk, M., Szmitkowski, M., & Ławicki, S. (2022) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0015.8844
李, 一. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1482280
Small molecular therapeutic targets for neurodegenerative diseases
Rangappa, N., Upadhyay, R., Lakshman, N., Ramasamy, S., Sevanan, M., Justin, A., & Chinnathambi, S. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.10.012
Saul, J., Hutchins, E. D., Reiman, R. A., Saul, M., Ostrow, L. W., Harris, B. T., Keuren‐Jensen, K. R. V., Bowser, R. P., & Bakkar, N. (2020) · Figshare · doi:10.6084/m9.figshare.12568889
Parkinson's disease and cardiovascular abnormalities: clinical and pathogenetic aspects
Sayfitdinkhuzhaev, Z. F., Жукова, Н. Г., Guseva, O. V., & Zhukova, I. A. (2026) · Annals of Clinical and Experimental Neurology · doi:10.17816/acen.1428
Metadata
- Authors
- Brkic, M., Balusu, S., Libert, C., & Vandenbroucke, R. E.
- Affiliations
- Ghent University (BE)
- Corresponding author
- Vandenbroucke, Roosmarijn E.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2015-01
- Volume
- 2015
- Issue
- 1
- Pages
- 620581-620581
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC4619970
- OpenAlex
- W2165521823
- Cited by
- 205
- References
- 310
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 19 · 2023: 12 · 2022: 24 · 2021: 36 · 2020: 28 · 2019: 13 · 2018: 24 · 2017: 22 · 2016: 8
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Education, Science and Technological Development of the Republic of Serbia (ON173056)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- matrix metalloproteinases, neurodegenerative diseases, neuroinflammation, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, matrix metalloproteinase inhibition, therapeutic target
- MeSH terms
- Alzheimer Disease, Amyotrophic Lateral Sclerosis, Animals, Humans, Huntington Disease, Inflammation, Multiple Sclerosis, Parkinson Disease, Biomarkers, Gene Expression Regulation, Enzymologic, Neurodegenerative Diseases, Matrix Metalloproteinases, Neurogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.